Vilin Bio Med Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Vilin Bio Med Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated).
As stated in Vilin Bio Med Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.
Based on Vilin Bio Med Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated). EBITDA for the quarter ended September 30, 2026: Rs. 179.77 lakhs, up 147% YoY (from Rs. 72.82 lakhs).
From Vilin Bio Med Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Vilin Bio Med's revenue grow in the September 2026 quarter?
- Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated)
- Revenue for the same quarter in the previous year (September 30, 2025): Rs. 966.40 lakhs
- Year-on-Year Increase in Revenue: Rs. 2,293.60 lakhs (approximately 238% increase)
What happened to Vilin Bio Med's margins in Q2 FY27?
See what Vilin Bio Med Ltd said on profitability & margins — free account, 30 seconds.
What capex is Vilin Bio Med planning?
See what Vilin Bio Med Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Vilin Bio Med raising money or cutting debt?
See what Vilin Bio Med Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Vilin Bio Med's order book?
More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vilin Bio Med Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vilin Bio Med Ltd Q2 FY27 results?
Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated). EBITDA for the quarter ended September 30, 2026: Rs. 179.77 lakhs, up 147% YoY (from Rs. 72.82 lakhs).
What is Vilin Bio Med Ltd share price analysis?
Vilin Bio Med Ltd currently shows a neutral. The stock trades at a P/E of 41.8 with a market cap of ₹81 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Vilin Bio Med Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
